RCUS Latest Headlines

Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials

at www.tipranks.com (Mon, 29-Dec 11:34 AM)

Arcus Halts STAR-221 Study, Sharpens Focus on Casdatifan and Next-Gen Inflammation Portfolio

Market Chameleon (Fri, 12-Dec 8:57 AM)

Arcus Biosciences Prices $250 Million Stock Offering—Key Takeaways for Investors

Market Chameleon (Fri, 31-Oct 9:11 AM)

Arcus Reports 26.7-Month Median Survival in Phase 2 EDGE-Gastric Study: New Hope for Advanced Gastric Cancer?

Market Chameleon (Mon, 13-Oct 8:17 AM)

Arcus Biosciences Reports Promising Casdatifan Results: 35% Response Rate and Robust Disease Control in Kidney Cancer Study

Market Chameleon (Mon, 6-Oct 11:27 AM)